Magazine Article | December 1, 2021

What's The Outlook From Life Science Operations For 2022 — And Beyond?

Source: Life Science Leader

By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL

In 2015, when we published our first manufacturing outlook article, biologics accounted for less than 5% of total sales. Perhaps that’s why the article only included “Pharma Manufacturing” in its title. What a difference six years make, as biologics in at least four countries now constitute more than 30% of total pharmaceutical sales. But, with the average daily dose of a biologic costing roughly 22 times more than a small molecule, it seems that leaders in biopharmaceutical manufacturing have never faced a greater challenge. Here’s what 12 biopharma manufacturing execs have to say as they look to 2022 and beyond.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader